Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23228211 | 0.85 | MKNK1 (0.33) | MKNK1KLK7DYRK1APDE4A | |
| SCHEMBL16417549 | 0.74 | SMN1; SMN2 (0.41) | MKNK1DYRK1APDE4A | |
| SCHEMBL17188315 | 0.70 | MAPT (0.45) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14306269 | 0.69 | MKNK1 (0.38) | MKNK1DYRK1APDE4APDE4BPDE4C | |
| SCHEMBL2763216 | 0.69 | MKNK1 (0.38) | MKNK1DYRK1APDE4APDE4BPDE4C | |
| SCHEMBL2764570 | 0.69 | KDM4E (0.50) | MKNK1DYRK1APDE4APDE4BPDE4C | |
| SCHEMBL19957717 | 0.69 | MKNK1 (0.42) | MKNK1DYRK1APDE4A | |
| SCHEMBL14325766 | 0.69 | MKNK1 (0.38) | MKNK1DYRK1APDE4A | |
| SCHEMBL19338489 | 0.69 | MKNK1 (0.38) | MKNK1DYRK1APDE4APDE4BPDE4C | |
| SCHEMBL11785295 | 0.69 | MKNK1 (0.38) | MKNK1DYRK1APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | MKNK1 129/4885KLK7 3128/4885DYRK1A 1855/4885 |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | MKNK1 78/4885KLK7 632/4885DYRK1A 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.